Jan 17th 2013 - Edison Investment Research today published a report on Verastem entitled "Targeting Cancer Stem Cells". In summary, the report says:
Verastem will shortly begin a series of studies that should provide definitive proof-of-concept for its cancer stem cell (CSC) hypothesis. The company plans to initiate Phase II trials of its lead compound, VS-6063, a FAK inhibitor that preclinical tests suggest is CSC-directed in mesothelioma and ovarian cancer. It also expects to advance VS-4718 and VS-5584, two CSC-directed compounds, into human clinical studies and decide on suitable indications thereafter. Verastem is well funded (>$90m cash) to reach the significant value inflection points associated with the results of these studies.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »